m5

Anti-Mouse MHC Class II (I-A/I-E) Antibody (M5/114) is an IgG2b antibody inhibitor derived from rats, specifically targeting mouse MHC Class II.

Anti-Mouse Thy1/CD90 Antibody (M5/49.4.1) is a rat-derived IgG2a antibody inhibitor targeting mouse Thy1/CD90.

Anti-CEACAM5/CEA/CD66e Antibody is a human-derived antibody expressed in CHO cells and targets CEACAM5/CEA/CD66e. It contains a huIgG1 heavy chain and a huκ light chain, with an estimated molecular weight (MW) of 145 kDa. For its isotype control, refer to HumanIgG1kappa, Isotype Control.

Anti-CEACAM5 Antibody (A5B7) is a human-derived antibody expressed in CHO cells, targeting CEACAM5/CEA/CD66e. It features a huIgG1 heavy chain and a huκ light chain, with an estimated molecular weight (MW) of 145 kDa. For isotype control, refer to HumanIgG1kappa, Isotype Control.

Anti-CEACAM5 Antibody (4H11-8) is a mouse IgG1, κ chimeric antibody designed to target human CEACAM5. The recommended isotype control for this antibody is Mouse IgG1 kappa, Isotype Control.

Anti-SARS-CoV-2 Omicron (BA.4/BA.5/BA.2.75) Spike RBD Specific Antibody (3M568) is a mouse (variable region) / human (kappa / IgG1 constant) chimeric monoclonal antibody targeting SARS-CoV-2 SARS-CoV-2 Omicron (BA.4/BA.5/BA.2.75) Spike RBD Specific.

hT84.66-M5A is a humanized IgG1 antibody targeting carcinoembryonic antigen (CEA). For an isotype control, refer to HumanIgG1kappa, Isotype Control.

ORM-5029 is the first antibody-drug conjugate (ADC) targeting the human epidermal growth factor receptor 2 (HER2), combining the highly potent GSPT1 degrader SMol006 with Pertuzumab. It is applicable in cancer research.

Brontictuzumab (OMP 52M5) is a monoclonal antibody that targets Notch1 and inhibits activation of the pathway. It has antitumor activity, inhibits tumor cell proliferation, and can be used in the study of leukemias and lymphomas.

Ormutivimab (rhRIG), a recombinant human monoclonal antibody designed to target the rabies virus, effectively neutralizes various strains and demonstrates strong efficacy as a post-exposure prophylaxis (PEP) treatment in model studies [1] [2].

Tusamitamab-MMAE is an antibody-drug conjugate (ADC) that combines a CEACAM5-targeted antibody with Monomethyl auristatin E (MMAE), designed for research in non-small cell lung cancer.